Last reviewed · How we verify
Homologous Blood Transfusion
Homologous blood transfusion replaces lost or deficient blood volume and cellular components to restore oxygen-carrying capacity and hemostatic function.
Homologous blood transfusion replaces lost or deficient blood volume and cellular components to restore oxygen-carrying capacity and hemostatic function. Used for Acute blood loss requiring volume and oxygen-carrying capacity restoration, Severe anemia, Coagulation disorders or thrombocytopenia requiring hemostatic support.
At a glance
| Generic name | Homologous Blood Transfusion |
|---|---|
| Also known as | Allogenic Blood Transfusion |
| Sponsor | Hamad Medical Corporation |
| Modality | Biologic |
| Therapeutic area | Hematology/Transfusion Medicine |
| Phase | Phase 3 |
Mechanism of action
This is a supportive therapeutic intervention that transfers whole blood or blood components from a donor to a recipient to treat acute blood loss, anemia, or coagulation deficiencies. The transfused red blood cells restore oxygen delivery to tissues, while plasma and platelets restore hemostatic capacity. It is a standard clinical procedure rather than a drug with a specific molecular mechanism.
Approved indications
- Acute blood loss requiring volume and oxygen-carrying capacity restoration
- Severe anemia
- Coagulation disorders or thrombocytopenia requiring hemostatic support
Common side effects
- Acute hemolytic transfusion reaction
- Febrile non-hemolytic transfusion reaction
- Allergic reaction
- Transfusion-related acute lung injury (TRALI)
- Infection transmission (viral, bacterial, parasitic)
- Iron overload (with chronic transfusion)
Key clinical trials
- Using DNA-Typing and Erythrocyte Microparticle Analysis to Detect Blood Doping (PHASE3)
- Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT) (PHASE2)
- A New Approach to a Personalized Patient Blood Management Program (pPBM) in Total Hip Arthroplasty (THA)
- Amicar Pharmacokinetics of Children Having Craniofacial Surgery (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Homologous Blood Transfusion CI brief — competitive landscape report
- Homologous Blood Transfusion updates RSS · CI watch RSS
- Hamad Medical Corporation portfolio CI